NEJM Retracts Avacopan Vasculitis Study - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

NEJM Retracts Avacopan Vasculitis Study

"The primary end-point assessments in nine patients were readjudicated after database lock and trial unblinding"

  • By

  • Kathryn Wighton

  • July 1, 2026

  • 3 min

Share

Clinical Scorecard: NEJM Retracts Avacopan Vasculitis Study

At a Glance

CategoryDetail
ConditionAntineutrophil cytoplasmic antibody-associated vasculitis
Key MechanismsUndisclosed changes to primary end point assessments following database lock and trial unblinding
Target PopulationPatients with newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis
Care SettingClinical trial setting

Key Highlights

  • The NEJM retracted the article evaluating avacopan due to undisclosed changes in primary end point assessments.
  • The FDA proposed withdrawing approval of Tavneos (avacopan) based on new information from an investigation.
  • The original analysis of the pivotal clinical study allegedly did not support the drug's effectiveness.
  • The ADVOCATE trial involved 331 patients and compared avacopan to a tapering regimen of prednisone.
  • The retraction follows a correction regarding glucocorticoid dose conversions published in January 2024.

Guideline-Based Recommendations

Diagnosis

    Management

    • Health care professionals should discuss available treatment options with patients regarding Tavneos.

    Monitoring & Follow-up

      Risks

      • Potential manipulation of study results by unblinded personnel.

      Patient & Prescribing Data

      Patients with granulomatosis with polyangiitis or microscopic polyangiitis.

      Avacopan was reported as noninferior to prednisone for remission at week 26 and superior for sustained remission at week 52, but these findings are now retracted.

      Clinical Best Practices

      • Ensure transparency in clinical trial reporting and endpoint assessments.
      • Monitor ongoing FDA evaluations regarding drug approvals.

      Related Resources & Content

      Original Source(s)

      NEJM Retracts Avacopan Vasculitis Study

      • by Kathryn Wighton

      • July 1, 2026

      Related Content

      Transdermal NSAID Matches Oral Celecoxib After Knee Replacement

      Randomized trial finds a topical anti-inflammatory patch provided similar pain relief, function, and safety as oral therapy during the first 6 weeks after surgery.

      Do Sitting Patterns Matter?

      Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

      Does Structured Reporting Improve Lung Cancer Reports?

      A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.